var data={"title":"Pembrolizumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pembrolizumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/752730?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pembrolizumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pembrolizumab: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pembrolizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pembrolizumab: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49726503\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Keytruda Safety Alert</span>\n      <span class=\"collapsible-date\">August 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has issued a safety alert regarding the risks associated with the use of Keytruda (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. The safety alert was prompted after data from two recently halted clinical trials demonstrated an increased risk of death with this combination.</p>\n        <p style=\"text-indent:0em;\">Keytruda is not approved for treatment of multiple myeloma, and other multiple myeloma clinical trials of Keytruda, other PD-1/PD-L1 cancer drugs, and other combinations are undergoing clinical evaluation to determine the extent of the safety issue.</p>\n        <p style=\"text-indent:0em;\">More information can be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm574347.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=f3x8JIhfxYA4kqpHd9hq6KCCaOrGOVni3kJcNlifizmALgrXV39ifX3hCkkuCk8QovKA161WDPAc7BA9YIemTID+0GZHrPPG/JOxqbQvm1w23l9otyhediWHbt34VmTyn+BdbW5ga4+ToLcjFbRDXgPzL3nR2SF8Qwz2Zs1DLhuP7vpDCr9eIOss5aF7T++d&amp;TOPIC_ID=96957\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm574347.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25871640\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Keytruda</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28575297\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Keytruda</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25808624\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-PD-1 Monoclonal Antibody;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25857279\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric cancer (recurrent locally advanced or metastatic): </b>IV: 200 <b>mg</b> once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Head and neck cancer, squamous cell, (recurrent or metastatic):</b> IV: 200 <b>mg</b> once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma, classical (relapsed or refractory):</b> IV: 200 <b>mg</b> once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma (unresectable or metastatic):</b> IV: 200 <b>mg</b> once every 3 weeks until disease progression or unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing: </i>2 mg/kg once every 3 weeks until disease progression or unacceptable toxicity (Ribas 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Microsatellite instability-high cancer (unresectable or metastatic): </b>IV: 200 <b>mg</b> once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (metastatic), single-agent therapy:</b> IV: 200 <b>mg</b> once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing </i>\n      <i>(in patients with disease progression following platinum-containing chemotherapy): </i>2 mg/kg once every 3 weeks for 24 months or until disease progression or unacceptable toxicity (Herbst 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (metastatic, nonsquamous), combination therapy:</b> IV: 200 <b>mg</b> once every 3 weeks (in combination with pemetrexed and carboplatin) for 4 cycles, followed by pembrolizumab monotherapy of 200 <b>mg</b> once every 3 weeks (with or without optional indefinite pemetrexed maintenance therapy) until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (Langer 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urothelial carcinoma (locally advanced or metastatic): </b>IV: 200 <b>mg</b> once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (Belmunt 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Merkel cell carcinoma, advanced (off-label use):</b> IV: 2 <b>mg/kg</b> once every 3 weeks for up to 2 years or until complete response, or until disease progression or unacceptable toxicity (Nghiem 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49729571\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pembrolizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pembrolizumab: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma, classical (relapsed or refractory):</b> Children &ge;2 years of age and Adolescents: IV: 2 <b>mg/kg</b> (maximum: 200 mg) once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Microsatellite instability-high cancer (unresectable or metastatic): </b>Children &ge;2 years of age and Adolescents: IV: 2 <b>mg/kg</b> (maximum: 200 mg) once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25860609\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25860610\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">No dosage adjustment necessary. In a pharmacokinetic study, no difference in clearance was noted for patients with eGFR &ge;15 mL/minute/1.73 m<sup>2</sup>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25860611\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment <b><i>prior </i></b>to treatment initiation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (total bilirubin &le; ULN and AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN and any AST): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) to severe (total bilirubin &gt;3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity <b><i>during </i></b>treatment:</i> <b>Note: </b>For patients with baseline grade 2 ALT or AST abnormalities due to liver metastases, permanently discontinue if AST or ALT increases by &ge;50% (relative to baseline) and persists at least 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST or ALT &gt;3 to 5 times ULN or total bilirubin &gt;1.5 to 3 times ULN: Withhold treatment; may resume therapy upon recovery to grade 0 or 1 toxicity. Also administer corticosteroids (prednisone 0.5 to 1 mg/kg/day [or equivalent] followed by a taper).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST or ALT &gt;5 times ULN or total bilirubin &gt;3 times ULN: Permanently discontinue. Also administer corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent] followed a taper).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25860612\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Withhold treatment for any of the following (may resume upon recovery to grade 0 or 1 toxicity):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Colitis, moderate (grade 2) or severe (grade 3); also administer corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent] followed by a taper).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic toxicity: Grade 3 severe skin reactions or suspected Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrinopathies:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hyperglycemia, severe; also administer antihyperglycemics.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hyperthyroidism, severe (grade 3) or life threatening (grade 4); manage with thionamides and beta-blockers as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypophysitis, grade 2 (symptomatic); also administer corticosteroids (followed by a taper) and hormone replacement therapy if appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic toxicity, grade 4 (in patients with classical Hodgkin lymphoma)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nephritis, grade 2; also administer corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent] followed by a taper).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pneumonitis, moderate (grade 2); also administer corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent] followed by a taper).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Other treatment-related toxicity, severe or grade 3; may require corticosteroids (based on severity). Upon improvement to grade 0 or 1, initiate corticosteroid taper and continue to taper over at least 1 month. Restart pembrolizumab if the adverse reaction remains at grade 0 or 1 following corticosteroid taper. May consider other systemic immunosuppressants if not controlled by corticosteroids (based on limited data).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Withhold (may resume upon recovery to grade 0 or 1 toxicity) or discontinue for: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hyperthyroidism, severe (grade 3) or life-threatening (grade 4); manage with thionamides and beta-blockers as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypophysitis, severe (grade 3) or life-threatening (grade 4); also administer corticosteroids and hormone replacement as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Permanently discontinue for:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adverse reactions that are life-threatening (excluding endocrinopathies controlled with hormone replacement therapy, or hematologic toxicity [in patients with classical Hodgkin lymphoma]), persistent grade 2 or 3 adverse reaction (excluding endocrinopathies controlled with hormone replacement therapy) that does not recover to grade 0 or 1 within 12 weeks after the last pembrolizumab dose, or any recurrent severe or grade 3 treatment-related adverse reaction. Also administer corticosteroids (may consider other systemic immunosuppressants if not controlled by corticosteroids [based on limited data]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Colitis, life-threatening (grade 4); also administer corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent] followed by a taper).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic toxicity: Grade 4 severe skin reactions or confirmed SJS or TEN.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immune mediated adverse reactions: Discontinue permanently if unable to reduce corticosteroid dose to prednisone &le;10 mg/day (or equivalent) within 12 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infusion-related reaction, grade 3 or 4.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nephritis, severe (grade 3) or life-threatening (grade 4); also administer corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent] followed by a taper).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pneumonitis, severe (grade 3), life-threatening (grade 4), or moderate (grade 2) that recurs; also administer corticosteroids (prednisone 1 to 2 mg/kg/day [or equivalent] followed by a taper).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25871641\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keytruda: 100 mg/4 mL (4 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keytruda: 50 mg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25871639\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116099\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s016lbl.pdf#page=34&amp;token=52PSnk3X9E5wvY9ss3Qad15MA/po/owG9GtPXLHhO/wh7cbohVJ5aJRqykD/oIs9Eo9DXudhw3IqY2rKUEXc9hovusSLwkQ241nyKXWTuJ5RjEcFrJA6zu5KDMLo067n&amp;TOPIC_ID=96957\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s016lbl.pdf#page=34</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25860614\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 30 minutes through a 0.2 to 5 micron sterile, nonpyrogenic, low-protein binding inline or add-on filter. Do not infuse other medications through the same infusion line.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Non-small cell lung cancer (metastatic):</i> When administered in combination with chemotherapy (pemetrexed and carboplatin), pembrolizumab should be administered prior to chemotherapy if scheduled to be administered on the same day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25808626\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric cancer (recurrent locally advanced or metastatic):</b> Treatment of recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients whose tumors express PD-L1 (combined positive score [CPS] &ge;1), as determined by an approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy, and if appropriate, HER2/neu-targeted therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Head and neck cancer, squamous cell (recurrent or metastatic):</b> Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in patients with disease progression on or after platinum-containing chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma, classical (relapsed or refractory)</b>: Treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma or patients who have relapsed after 3 or more prior lines of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma (unresectable or metastatic):</b> Treatment of unresectable or metastatic melanoma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Microsatellite instability-high cancer (unresectable or metastatic): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Solid tumors:</i> Treatment of unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors in adult and pediatric patients that have progressed following prior treatment and have no satisfactory alternate treatment options.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitation of use: Safety and efficacy in pediatric patients with MSI-H central nervous system cancers have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Colorectal cancer:</i> Treatment of unresectable or metastatic, MSI-H or mismatch repair deficient colorectal cancer in patients that have progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (metastatic):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First-line, single-agent treatment of metastatic non-small cell lung cancer (NSCLC) in patients with tumors with high PD-L1 expression (tumor proportion score [TPS] &ge;50%), as determined by an approved test, and with no EGFR or ALK genomic tumor aberrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First-line treatment (in combination with pemetrexed and carboplatin) of metastatic nonsquamous NSCLC</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Single-agent treatment of metastatic NSCLC in patients with tumors with PD-L1 expression (TPS &ge;1%), as determined by an approved test, and with disease progression on or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression (on approved EGFR- or ALK-directed therapy) prior to receiving pembrolizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urothelial carcinoma (locally advanced or metastatic):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of locally advanced or metastatic urothelial cancer in patients who are not eligible for cisplatin-containing treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of locally advanced or metastatic urothelial cancer in patients with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47057381\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Merkel cell carcinoma (advanced)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25857263\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pembrolizumab may be confused with atezolizumab, nivolumab, palivizumab, panitumumab</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26125002\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence of adverse reactions include unapproved dosing regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (26% to 43%), headache (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (11% to 28%), skin rash (20% to 24%; immune-mediated: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (49%), hypoalbuminemia (37%), hyponatremia (10% to 37%), hypertriglyceridemia (33%), decreased serum phosphate (29%), increased serum potassium (28%), decreased serum bicarbonate (22%), hypocalcemia (21%), hypothyroidism (immune-mediated; 9% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite (20% to 22%), constipation (19% to 22%), nausea (13% to 22%), diarrhea (18% to 20%), abdominal pain (13% to 18%), vomiting (12% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (15% to 19%), hematuria (12% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (17% to 44%; grades 3/4: 6% to 10%), lymphocytopenia (40%; grades 3/4: 9%), thrombocytopenia (27%; grades 3/4: 4%), neutropenia (24%; grades 3/4: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (17% to 37%), increased serum AST (24% to 28%), increased serum ALT (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (21% to 32%), arthralgia (10% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (11% to 35%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (14% to 24%), dyspnea (11% to 14%), upper respiratory tract infection (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (11% to 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Facial edema (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Peripheral neuropathy (2% to 10%), confusion (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (10%), hyperthyroidism (immune-mediated; 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Colitis (immune-mediated; 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urosepsis (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes zoster (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (10%), arthritis (immune-mediated; 2%), myositis (immune-mediated; &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Uveitis (immune-mediated; &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonitis (3%), pleural effusion (&ge;2%), respiratory failure (&ge;2%), pneumonia (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion-related reaction (&le;9%; including anaphylaxis, hypersensitivity reaction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Adrenocortical insufficiency (immune-mediated), bullous pemphigoid (immune-mediated), chronic inflammatory demyelinating polyradiculoneuropathy (Maleissye 2016), diabetic ketoacidosis, exfoliative dermatitis (immune-mediated), Guillain-Barr&eacute; syndrome (immune-mediated), hemolytic anemia (immune-mediated), hepatitis (including autoimmune hepatitis), hypophysitis, interstitial nephritis (with renal failure), myasthenia gravis (immune-mediated), myelitis (immune-mediated), myocarditis (immune-mediated), nephritis (autoimmune), organ transplant rejection (solid; immune-mediated), pancreatitis (immune-mediated), partial epilepsy (immune-mediated; in a patient with inflammatory foci in brain parenchyma), septic shock, thyroiditis, type 1 diabetes mellitus, vasculitis (immune-mediated)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25808627\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to pembrolizumab or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25857268\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN, some fatal), exfoliative dermatitis, and bullous pemphigoid may occur with pembrolizumab. Monitor for suspected severe skin reactions and exclude other causes. Based on the severity of the dermatologic toxicity, withhold or permanently discontinue pembrolizumab and administer corticosteroids. Withhold pembrolizumab for signs/symptoms of SJS or TEN and refer for specialized care for assessment and management. Permanently discontinue pembrolizumab if SJS or TEN is confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Type 1 diabetes mellitus has occurred (including diabetic ketoacidosis). Monitor closely for hyperglycemia and other signs/symptoms of diabetes. Insulin therapy may be required; if severe hyperglycemia is observed, administer antihyperglycemics and withhold pembrolizumab treatment until glucose control has been accomplished.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Immune-mediated colitis has occurred, including cases of grade 2 to 4 colitis. The median time to onset of colitis was 3.5 months (range: 10 days to 16.2 months) and the median duration was 1.3 months (range: 1 day to over 8 months). In many patients, colitis was managed with high-dose systemic corticosteroids for a median duration of 7 days (range: 1 day to 5.3 months), followed by a corticosteroid taper. Most patients with colitis experienced resolution. May require treatment interruption, systemic corticosteroid therapy, and/or permanent discontinuation. Monitor for signs and symptoms of colitis; administer systemic corticosteroids for grade 2 or higher colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Immune-mediated hepatitis occurred (grades 2 to 4 hepatitis). The median onset for hepatitis was 1.3 months (range: 8 days to 21.4 months); the median duration was 1.8 months (range: 8 days to over 20 months). Hepatitis resolved in most patients. Administer corticosteroids (prednisone 0.5 to 1 mg/kg/day [or equivalent] for grade 2 hepatitis, and prednisone 1 to 2 mg/kg/day [or equivalent] for grade 3 or higher, each followed by a taper), and withhold or discontinue therapy based on the severity of liver enzyme elevations. Systemic corticosteroids were used to manage immune-mediated hepatitis in many patients; the median duration of high-dose corticosteroid therapy was 5 days (range: 1 to 26 days), followed by a taper. Monitor for liver function changes. May require treatment interruption, systemic corticosteroids (for grade 2 or higher toxicity), and/or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity and anaphylaxis have been observed (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypophysitis: Immune-mediated hypophysitis occurred (grades 2, 3, and 4). The median time to onset was 3.7 months (range: 1 day to 12 months) and the median duration was 4.7 months (range: 8 days to over 12 months). Most cases were managed with systemic corticosteroids. Nearly half of patients with hypophysitis experienced resolution. Monitor for signs/symptoms of hypophysitis (eg, hypopituitarism, adrenal insufficiency). May require treatment interruption, systemic corticosteroids and hormone replacement therapy (as clinically indicated), and/or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion-related reactions: Infusion-related reactions (including severe and life-threatening cases) have occurred. Monitor for signs/symptoms of a reaction (eg, rigors, chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever). Interrupt infusion and permanently discontinue for severe (grade 3) or life-threatening (grade 4) infusion-related reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Immune-mediated nephritis has occurred. The onset for autoimmune nephritis was 5.1 months (range: 12 days to 12.8 months) and the median duration was 3.3 months (range: 12 days to over 9 months). Grade 2 or higher nephritis should be managed with systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg/day [or equivalent], followed by a taper). Most patients required systemic corticosteroids. The median duration of corticosteroid use was 15 days (range: 3 days to 4 months), followed by a taper. Nephritis resolved in over half of affected patients. Monitor for renal function changes. May require treatment interruption, systemic corticosteroids (for grade 2 or higher toxicity), and/or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Immune-mediated pneumonitis has been observed, including fatal cases. The median time to development was 3.3 months (range: 2 days to ~19 months) and the median duration was 1.5 months (range: 1 day to over 17 months). Many patients required initial management with high-dose systemic corticosteroids; the median duration of initial corticosteroid therapy was 8 days (range: 1 day to ~10 months) followed by a corticosteroid taper. Pneumonitis resolved in half of the affected patients. May require treatment interruption, corticosteroid therapy (prednisone 1 to 2 mg/kg /day [or equivalent] followed by a taper, for grade 2 or higher pneumonitis), and/or permanent discontinuation. Monitor for signs and symptoms of pneumonitis; if pneumonitis is suspected, evaluate with radiographic imaging and administer systemic corticosteroids for grade 2 or higher pneumonitis. Pneumonitis occurred more frequently in patients with a history of prior thoracic radiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Immune-mediated hyperthyroidism, hypothyroidism, and thyroiditis have occurred. The median onset for hyperthyroidism was 1.4 months (range: 1 day to ~22 months) and the median duration was 2.1 months (range: 3 days to over 15 months). Hyperthyroidism resolved in nearly three-fourths of affected patients. Hypothyroidism occurred with a median onset of 3.5 months (range: 1 day to 19 months) and median duration was not reached (range: 2 days to over 27 months). Hypothyroidism resolved in one-fifth of affected patients. The incidence of new or worsening hypothyroidism was higher in patients with squamous cell cancer of the head and neck. Monitor for changes in thyroid function (at baseline, periodically during treatment, and as clinically indicated) and for signs/symptoms of thyroid disorders. Administer thionamides and beta-blockers for hyperthyroidism as appropriate; may require treatment interruption and/or permanent discontinuation. Isolated hypothyroidism may be managed with replacement therapy. Thyroiditis occurred with a median onset of 1.2 months (range 0.5 to 3.5 months).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Other immune-mediated toxicities: Other clinically relevant immune-mediated disorders have been observed (may involve any organ system), including rash, exfoliative dermatitis, bullous pemphigoid, uveitis, arthritis, vasculitis, myositis, Guillain-Barr&eacute; syndrome, pancreatitis, hemolytic anemia, serum sickness, myasthenia gravis, myelitis, myocarditis, and partial seizures (in a patient with inflammatory foci in brain parenchyma). If an immune-mediated adverse event is suspected, evaluate appropriately to confirm or exclude other causes; withhold treatment and administer systemic corticosteroids based on severity of reaction. Upon resolution to grade 0 or 1, initiate corticosteroid taper (continue tapering over at least 1 month). When reaction remains at grade 1 or less during taper may reinitiate pembrolizumab. Immune-mediated adverse reactions that do not resolve with systemic corticosteroids may be managed with other systemic immunosuppressants (based on limited data). Discontinue permanently for severe or grade 3 immune-mediated adverse event that is recurrent or life-threatening.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorders: Anti-PD-1 monoclonal antibodies generate an immune response that may aggravate underlying autoimmune disorders or prior immune-related adverse events. A retrospective study analyzed the safety and efficacy of treatment with anti-PD-1 monoclonal antibodies (eg, pembrolizumab, nivolumab) in melanoma patients with preexisting autoimmune disease or prior significant ipilimumab-mediated adverse immune events. Results showed that while immune toxicities associated with this class of therapy did occur, most reactions were mild and easily manageable and did not require permanent drug therapy discontinuation. A significant percentage of patients achieved clinical response with anti-PD-1 monoclonal antibody therapy, despite baseline autoimmunity or prior ipilimumab-related adverse events (Menzies 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematopoietic stem cell transplant: Patients who received allogeneic hematopoietic stem cell transplant (HSCT) following discontinuation of pembrolizumab therapy experienced immune-mediated complications (some fatal) including graft versus host disease (GVHD) and severe sinusoidal obstructive syndrome (SOS; formerly called veno-occlusive disease) following reduced-intensity conditioning. Fatal hyperacute GVHD post HSCT has also been reported in lymphoma patients who received an anti PD-1 antibody prior to transplant. These complications may occur despite intervening therapy between pembrolizumab and HSCT. Monitor closely for early signs/symptoms of transplant-related complications (eg, hyperacute GVHD, severe [grade 3 to 4] acute GVHD, steroid-requiring febrile syndrome, SOS, and other immune-mediated adverse reactions) and manage promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: An increase in mortality was noted in 2 clinical studies in patients with multiple myeloma who received pembrolizumab in combination with a thalidomide analogue and dexamethasone. Causes of death in the experimental arm (containing pembrolizumab, dexamethasone, and a thalidomide analogue [pomalidomide or lenalidomide]) included myocarditis, Stevens-Johnson syndrome, MI, pericardial hemorrhage, cardiac failure, respiratory tract infection, neutropenic sepsis, sepsis, multiple organ dysfunction, respiratory failure, intestinal ischemia, cardiopulmonary arrest, suicide, pulmonary embolism, cardiac arrest, pneumonia, sudden death, and large intestine perforation. Multiple myeloma is not an approved indication for PD-1 or PD-L1 blocking antibodies; pembrolizumab should not be used to treat multiple myeloma in combination with a thalidomide analogue and dexamethasone unless as part of a clinical trial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Solid organ transplant: Solid organ transplant rejection has been reported in postmarketing surveillance. Pembrolizumab may increase the risk of rejection; consider benefit versus risk of pembrolizumab treatment in solid organ transplant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Select patients for metastatic gastric cancer and non-small cell lung cancer (NSCLC) single agent treatment based on PD-L1 expression. If PD-L1 expression is not detected in a gastric cancer archived specimen, evaluate feasibility of obtaining a tumor biopsy to test for PD-L1 expression. Information on tests to detect PD-L1 expression in gastric cancer or NSCLC may be found at <a target=\"_blank\" href=\"http://www.fda.gov/companiondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ/rX/FBRnAtp+YOOMBGgh36vrA79ff4L/MZW&amp;TOPIC_ID=96957\" target=\"_blank\">http://www.fda.gov/companiondiagnostics</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25882853\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25882850\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=96957&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide Analogues: Pembrolizumab may enhance the adverse/toxic effect of Thalidomide Analogues. Specifically, mortality may be increased when this combination is used for treatment of refractory multiple myeloma. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25857265\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Immunoglobulins are known to cross the placenta; therefore fetal exposure to pembrolizumab is expected. Based on the mechanism of action, pembrolizumab may cause fetal harm if administered during pregnancy; an alteration in the immune response or immune mediated disorders may develop following in utero exposure. Women of reproductive potential should use highly effective contraception during therapy and for at least 4 months after treatment is complete.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25857267\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pembrolizumab is present in breast milk. The manufacturer recommends that breastfeeding be discontinued during therapy and for 4 months following the final dose. Immunoglobulins are excreted in breast milk; therefore pembrolizumab may be expected to appear in breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25860616\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">PD-L1 expression status in patients with gastric cancer or non-small cell lung cancer (NSCLC, when used as single-agent therapy); liver function tests (AST, ALT, and total bilirubin); renal function; thyroid function (at baseline, periodically during treatment and as clinically indicated); glucose; CBC with differential (in patients with Hodgkin lymphoma); signs/symptoms of colitis, dermatologic toxicity, hypophysitis, thyroid disorders, pneumonitis, infusion reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25857273\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pembrolizumab is a highly selective anti-PD-1 humanized monoclonal antibody which inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor on T-cells to block PD-1 ligands (PD-L1 and PD-L2) from binding. Blocking the PD-1 pathway inhibits the negative immune regulation caused by PD-1 receptor signaling (Hamid 2013). Anti-PD-1 antibodies (including pembrolizumab) reverse T-cell suppression and induce antitumor responses (Robert 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25857275\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Clearance is ~23% lower at steady state than with the first dose. With weight-based dosing (2 mg/kg), pembrolizumab concentrations in pediatric patients are comparable to those of adults (at the same dose).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 6 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 22 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116586\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Keytruda Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/4 mL (4 mL): $5,497.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Keytruda Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $2,628.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45649755\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Keytruda (AT, AU, CH, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, IE, IL, IS, JP, KR, LT, LU, MY, NL, NO, NZ, PH, PL, PT, RO, SE, SG, SI, SK, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28212060\"></a>Bellmunt J, de Wit R, Vaughn DJ, et al; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. <i>N Engl J Med</i>. 2017;376(11):1015-1026. doi: 10.1056/NEJMoa1613683.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28212060/pubmed\" target=\"_blank\" id=\"28212060\">28212060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. <i>Ann Oncol</i>. 2016;27(4):559-574. doi: 10.1093/annonc/mdv623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26715621/pubmed\" target=\"_blank\" id=\"26715621\">26715621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen R, Zinzani PL, Fanale MA, et al; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. <i>J Clin Oncol</i>. 2017;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28441111/pubmed\" target=\"_blank\" id=\"28441111\">28441111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs CS, Doi T, Woo-Jun Jang R, et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer [abstract]. <i>J Clin Oncol</i>. 2017;35(18s); abstr 4003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28441111/pubmed\" target=\"_blank\" id=\"28441111\">28441111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. <i>N Engl J Med</i>. 2015;372(21):2018-2028.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/25891174/pubmed\" target=\"_blank\" id=\"25891174\">25891174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>N Engl J Med</i>. 2013;369:134-144.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/23724846/pubmed\" target=\"_blank\" id=\"23724846\">23724846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet</i>. 2016;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26712084/pubmed\" target=\"_blank\" id=\"26712084\">26712084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>J Clin Oncol</i>. 2016;34(13):1510-1517. doi: 10.1200/JCO.2015.64.0391.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26951310/pubmed\" target=\"_blank\" id=\"26951310\">26951310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keytruda (pembrolizumab) [prescribing information]. Whitehouse Station, NJ: Merck; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keytruda (pembrolizumab) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncol</i>. 2016;17(11):1497-1508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27745820/pubmed\" target=\"_blank\" id=\"27745820\">27745820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>N Engl J Med</i>. 2015;372(26):2509-2520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26028255/pubmed\" target=\"_blank\" id=\"26028255\">26028255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maleissye M, Nicolas G, Saiag P. Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. <i>N Engl J Med</i>. 2016;375(3):296-297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27468083/pubmed\" target=\"_blank\" id=\"27468083\">27468083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehra R, Seiwert TY, Mahipal A, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012. <i>J Clin Oncol</i>. 2016:34(18s); abstr 6012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <i>Ann Oncol</i>. 2017;28(2):368-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27687304/pubmed\" target=\"_blank\" id=\"27687304\">27687304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27093365\"></a>Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>N Engl J Med</i>. 2016;374(26):2542-2552. doi: 10.1056/NEJMoa1603702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27093365/pubmed\" target=\"_blank\" id=\"27093365\">27093365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reck M, Rodr&iacute;guez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer [published online October 8, 2016]. <i>N Engl J Med</i>. 2016;375(19):1823-1833.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27718847/pubmed\" target=\"_blank\" id=\"27718847\">27718847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ribas A, Puzanov I, Dummer R, et al, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncol</i>. 2015 Aug;16(8):908-918.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26115796/pubmed\" target=\"_blank\" id=\"26115796\">26115796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizvi NA, Garon EB, Leighl N, et al. Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1&ndash;positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001 [abstract]. <i>J Clin Oncol</i>. 2015;33(18s); abstr 8026.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet</i>. 2014;384(9948):1109-1117.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/25034862/pubmed\" target=\"_blank\" id=\"25034862\">25034862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robert C, Schachter J, Long GV, et al; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>N Engl J Med</i>. 2015;372(26):2521-2532.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/25891173/pubmed\" target=\"_blank\" id=\"25891173\">25891173</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 96957 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F49726503\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F25871640\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28575297\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F25808624\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F25857279\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F49729571\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F25860609\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25860610\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25860611\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F25860612\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F25871641\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F25871639\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F26116099\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25860614\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F25808626\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F47057381\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25857263\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F26125002\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25808627\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F25857268\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F25882853\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F25882850\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F25857265\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F25857267\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25860616\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F25857273\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F25857275\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26116586\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45649755\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/96957|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pembrolizumab-patient-drug-information\" class=\"drug drug_patient\">Pembrolizumab: Patient drug information</a></li><li><a href=\"topic.htm?path=pembrolizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">Pembrolizumab: Pediatric drug information</a></li></ul></div></div>","javascript":null}